Drug Overview
Lonafarnib is a highly specialized medicine. It acts as a Targeted Therapy. Originally, scientists created it to fight cancer. Today, it is famous for being the first medicine ever approved to treat a rare, rapid aging disease in children called Progeria.
- Generic name: Lonafarnib
- US Brand names: Zokinvy
- Drug Class: Farnesyltransferase inhibitor, Targeted Therapy
- Route of Administration: Oral (taken by mouth as a capsule)
- FDA Approval Status: Fully approved by the FDA for specific genetic aging diseases. It is not FDA approved for cancer, though it is still studied in cancer research.
What Is It and How Does It Work? (Mechanism of Action)

Lonafarnib is a Targeted Therapy designed to block a specific machine in your cells. This machine is an enzyme called farnesyltransferase.
Here is how the drug works at the molecular level:
Normally, the farnesyltransferase enzyme acts like a delivery driver. It attaches a sticky fat molecule, called a farnesyl group, to certain proteins. This sticky fat allows the proteins to glue themselves to the cell’s outer wall or the wall of the cell’s command center (the nucleus).
In cancer cells, a protein called Ras uses this sticky fat to attach to the cell wall and send signals that tell the tumor to grow. In the rapid aging disease Progeria, a broken protein called progerin uses this sticky fat to attach to the nucleus. This broken protein damages the nucleus, causing the cells to age and die very quickly.
When a patient takes lonafarnib, the medicine blocks the enzyme. Because the enzyme is blocked, the sticky fat is never attached to the proteins. The bad proteins can no longer attach to the cell walls. In cancer research, this starves the tumor of growth signals. In Progeria, this protects the cell’s command center, stopping the rapid aging process and allowing the cells to live longer, healthier lives.
FDA-Approved Clinical Indications
Because this medicine is so unique, its approved uses are very specific.
Oncological uses:
- None at this time. (It was studied for cancers like lung cancer and leukemia, but it is currently investigational and not approved for these diseases).
Non oncological uses:
- Hutchinson Gilford Progeria Syndrome (a rare disease that causes rapid aging in children).
- Processing deficient Progeroid Laminopathies (other rare genetic diseases that cause rapid aging).
Dosage and Administration Protocols
This medicine is taken by mouth at home. The dose is carefully calculated by the doctor based on the patient’s height and weight, known as body surface area.
| Treatment Phase | Standard Dose | Frequency of Administration | Administration Notes |
| Starting Dose | 115 milligrams per square meter of body surface area | Twice a day | Must be taken with the morning and evening meals |
| Maintenance Dose | 150 milligrams per square meter of body surface area | Twice a day | Started after 4 months of taking the starting dose |
Dose adjustments for organ problems:
If a patient has severe kidney problems, doctors must be very careful, as the drug was not heavily tested in these patients. If a patient has liver problems, or if they take other medicines that affect the liver, the doctor may need to lower the lonafarnib dose by half. This prevents the medicine from building up to dangerous levels in the blood.
Clinical Efficacy and Research Results
Recent clinical studies from 2020 to 2025 show incredible results for children with Progeria. Before this drug, children with Progeria had an average life expectancy of only 14.5 years.
In long term studies matching treated patients against untreated patients, lonafarnib lowered the risk of death by 77 percent. Patients who took the medicine lived an average of 2.5 years longer than those who did not. While it is not a complete cure, it significantly slows down the disease progression and protects the heart and blood vessels from early damage.
In cancer research, recent 2024 and 2025 studies are looking at combining lonafarnib with other modern drugs to treat advanced non small cell lung cancer and certain blood cancers. While it did not work well alone in older trials, new combination therapies are showing promise in shrinking tumors that do not respond to standard chemotherapy.
Safety Profile and Side Effects
Because this medicine changes how cells build proteins, it can cause uncomfortable side effects, especially in the stomach and intestines.
Common side effects (Occurring in greater than 10 percent of patients):
- Vomiting and severe nausea.
- Diarrhea.
- Decreased appetite and weight loss.
- Feeling very tired (fatigue).
- Upper respiratory tract infections (like a cold).
- Increased liver enzymes in the blood.
Serious adverse events:
- Severe dehydration from vomiting and diarrhea.
- Electrolyte imbalances (dangerous drops in blood salt levels).
- Kidney damage (nephrotoxicity).
- Eye and vision problems (retinal abnormalities).
Black Box Warning:
This medicine does not have a formal FDA Black Box Warning. However, it comes with strict warnings against taking it with certain strong medicines, like cholesterol drugs (statins) or strong antibiotics, because mixing them can cause life threatening reactions.
Management strategies:
Because stomach problems are so common, doctors strongly recommend taking the medicine with a full meal. If a patient experiences severe vomiting or diarrhea that leads to weight loss, the doctor will lower the dose back to the starting level. Patients are also given anti nausea and anti diarrhea medicines to help them stay comfortable.
Connection to Stem Cell and Regenerative Medicine (If Applicable)
Research Areas:
Lonafarnib plays an exciting role in the study of cellular regeneration and aging. In Progeria, the body’s cells become old and damaged very quickly, a process called cellular senescence. By protecting the cell’s nucleus, lonafarnib helps regenerate the normal shape and function of the cell. Today, scientists in regenerative medicine are studying how to combine lonafarnib with new gene editing tools, like CRISPR, and stem cell therapies. The goal is to use lonafarnib to protect the cells while stem cells replace the damaged tissues, potentially reversing the rapid aging process entirely.
Patient Management and Practical Recommendations
To keep patients safe and ensure the medicine works perfectly, medical teams follow strict rules.
Pre-treatment tests to be performed:
- Complete blood tests to check liver health.
- Tests to measure blood salt levels (electrolytes).
- An electrocardiogram to check the heart’s electrical rhythm, as the drug can affect heartbeats.
- A complete review of all other medicines the patient takes.
Precautions during treatment:
- The medicine must be monitored closely for the first four months when stomach side effects are the worst.
- Vision should be checked regularly to watch for eye changes.
Do’s and Don’ts list:
- Do take the capsules whole with a sufficient amount of water.
- Do mix the capsule contents with applesauce or orange juice if the patient cannot swallow pills, and drink it within 10 minutes.
- Do drink plenty of water every day to prevent dehydration from diarrhea.
- Do tell your doctor immediately if you feel dizzy or have a very fast heartbeat.
- Do not chew the capsules.
- Do not drink grapefruit juice or eat Seville oranges (bitter oranges), as these can cause the drug to build up to toxic levels in the body.
- Do not start any new vitamin, herbal supplement, or prescription drug without asking your doctor first.
Legal Disclaimer
The medical information provided in this guide is for educational and informational purposes only and is not meant to replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition, genetic testing, or treatment options. Do not disregard professional medical advice or delay seeking it because of something you have read in this material.